Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A gene variant found mostly on one island could reshape breast cancer screening

NCT ID NCT05898009

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers want to know how common a BRCA2 gene mutation is among people diagnosed with breast cancer on Reunion Island. Earlier work found that more than half of patients there with a BRCA mutation carry a variant specific to the island's population. This study collects blood samples from about 228 residents with a first or second breast cancer to measure how often that mutation appears. The goal is to help doctors decide who should get genetic counseling and preventive care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a blood sample tested for a BRCA2 gene mutation
What this could lead to
If the mutation turns out to be common, doctors could offer genetic counseling and preventive care to more families on Reunion Island.
What could go wrong
This study only counts how often the mutation appears. It cannot show whether testing or preventive steps save lives, and its findings may apply only to people living on Reunion Island.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

228 people

The number who actually took part.

Started

Oct 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Domiciled in Reunion at the time of the diagnosis * Who is diagnosed with a first breast cancer (in situ or invasive) confirmed by anatomopathological examination during the inclusion period Or Who is diagnosed with a second breast cancer (in situ or invasive) confirmed by pathological examination during the inclusion period, contralateral to the first or at least 5 years after remission of the first * Having agreed to participate in the study; * Affiliates or beneficiaries of a social security scheme Exclusion Criteria: * Carriers of breast lymphoma, * Minor patients or patients under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA2 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA2-related cancer predisposition breast cancer breast neoplasm hereditary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA2 mutation Breast cancer Genetic disease

Contacts and locations

Locations

  • Mireille IRABE

    Saint-Pierre, 97432, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.